BOSTON--(BUSINESS WIRE)--Mar. 8, 2016--
Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing
drugs to treat cancer, today announced that the Company will present at
the 28th Annual ROTH Conference on Tuesday, March 15 at 12:00
p.m. PT at the Ritz-Carlton in Dana Point, CA.
A live webcast of the presentation will be available on the company's
website at www.verastem.com.
An archived presentation will be available for 90 days.
About Verastem, Inc.
Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on
discovering and developing drugs to improve outcomes for patients with
cancer. Our product candidates utilize a multi-faceted approach to treat
cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and
modulating the local tumor microenvironment. Our most advanced clinical
product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and
VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more
information, please visit www.verastem.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160308005397/en/
Source: Verastem, Inc.
Verastem, Inc.
Brian Sullivan, 781-292-4214
bsullivan@verastem.com
